|
|
|
|
|
|
by mcarmichael
2243 days ago
|
|
|
Derek Lowe is terrific in communicating complex ideas in the field to concerned lay observers like me; he's been a great resource for reliable information about the science of this thing. Just to clarify; the ChAdOx1 MERS prospect hasn't proceeded to a trial demonstrating efficacy in human subjects (as yet). That's a particularly important distinction here, given the nature of the novel delivery mechanism[1] and prior observation of complications in SARS-CoV-1 vaccine development[2] [1] https://en.wikipedia.org/wiki/Viral_vector#Adenoviruses [2] https://www.hkmj.org/abstracts/v22n3%20Suppl%204/25.htm |
|
|
Looks like it has (for SARS-CoV-2 instead): https://www.genengnews.com/news/astrazeneca-joins-u-of-oxfor...